Did Polivy Clinical Trials Include Children?
Polivy (polatuzumab vedotin-piiq), an antibody-drug conjugate for relapsed or refractory diffuse large B-cell lymphoma (DLBCL) in adults, has no publicly reported clinical trials involving pediatric patients (under 18). Its FDA approval in 2019 was based solely on adult data from trials like GO29365.[1]
Why No Children in Polivy Studies?
Polivy's development targeted adults with aggressive lymphomas, which are rarer in children. Pediatric lymphomas more often involve Burkitt or lymphoblastic types, where other therapies (e.g., chemotherapy regimens) dominate. No pediatric-specific trials appear in ClinicalTrials.gov searches for polatuzumab vedotin, and the prescribing information limits use to adults 18+.[2][3]
What Happens If Used Off-Label in Kids?
No efficacy or safety data exists for children, so off-label use is not recommended. The drug's black-box warnings for adult severe side effects—like neutropenia, infections, and peripheral neuropathy—raise similar risks in pediatrics without dosing studies.[3] Oncologists rely on adult extrapolation cautiously, but pediatric approval would need dedicated trials under FDA's pediatric oncology rules.
Alternatives for Pediatric Lymphoma
Children with DLBCL typically receive intensive chemo like R-CHOP variants or rituximab-based regimens, with cure rates over 80-90%.[4] CAR-T therapies (e.g., Yescarta, approved for pediatrics in some B-cell lymphomas) or bispecific antibodies serve relapsed cases. Biosimilars or generics aren't relevant yet for Polivy.
Ongoing Pediatric Research or Patents?
No active pediatric Polivy trials listed. Genentech/Roche holds patents until ~2030-2033; DrugPatentWatch.com shows no pediatric extensions or challenges tied to kids.[5] Future studies could emerge if adult data supports expansion, but none are registered.
Sources:
[1] FDA Polivy Label (fda.gov)
[2] ClinicalTrials.gov (search: polatuzumab vedotin pediatric)
[3] Polivy Prescribing Information (gene.com)
[4] COG Pediatric Lymphoma Guidelines (childrensoncologygroup.org)
[5] DrugPatentWatch.com/drugs/polatuzumab-vedotin